In this section
@article{Mullish:2021:10.26355/mhd_20219_586,
author = {Mullish, BH and Alexander, JL and Segal, JP},
doi = {10.26355/mhd_20219_586},
journal = {Microbiota in Health and Disease},
title = {Microbiota and faecal microbiota transplant},
url = {http://dx.doi.org/10.26355/mhd_20219_586},
volume = {3},
year = {2021}
}
TY - JOUR
AB - As the range of disease states associated with the gut microbiome expands - and the mechanistic links between the gut microbiome and host physiology further deepens – so interest also grows in microbiome manipulation as medical therapy. In particular, bolstered by its established role in recurrent C. difficile infection (and promising results in other conditions), faecal microbiota transplant (FMT) has remained of growing global focus. This article reviews the key FMT-based studies published between April 2020 - March 2021. While the COVID-19 pandemic was the dominant challenge of the year, important FMT trials of interest were published for patients with a range of different conditions. The emergence of ‘next generation’ microbiome therapeutics offers an additional perspective and new opportunities within the field.
AU - Mullish,BH
AU - Alexander,JL
AU - Segal,JP
DO - 10.26355/mhd_20219_586
PY - 2021///
SN - 2704-8845
TI - Microbiota and faecal microbiota transplant
T2 - Microbiota in Health and Disease
UR - http://dx.doi.org/10.26355/mhd_20219_586
UR - https://www.microbiotajournal.com/article/586
UR - http://hdl.handle.net/10044/1/89442
VL - 3
ER -
For any enquiries about the Microbiome Network at Imperial, please contact: